Tag Archives: SRPT

Sarepta Therapeutics (SRPT) Gets a Buy Rating from Credit Suisse

Credit Suisse analyst Martin Auster maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report) yesterday and set a price target of $185.00. The company’s shares closed last Thursday at $126.25. According to TipRanks.com, Auster is a 5-star analyst

Sarepta Therapeutics (SRPT) Receives a Hold from Oppenheimer

Oppenheimer analyst Hartaj Singh maintained a Hold rating on Sarepta Therapeutics (SRPT – Research Report) today. The company’s shares closed last Wednesday at $122.57. According to TipRanks.com, Singh is a 5-star analyst with an average return of 8.6% and a

RBC Capital Sticks to Its Buy Rating for Sarepta Therapeutics (SRPT)

In a report released today, Brian Abrahams from RBC Capital maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), with a price target of $182.00. The company’s shares closed last Wednesday at $121.22. According to TipRanks.com, Abrahams is

Mizuho Securities Maintains a Buy Rating on Sarepta Therapeutics (SRPT)

Mizuho Securities analyst Difei Yang maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report) today and set a price target of $183.00. The company’s shares closed last Wednesday at $117.09. According to TipRanks.com, Yang is currently ranked with

Sarepta Therapeutics (SRPT) Gets a Buy Rating from Morgan Stanley

In a report released today, Matthew Harrison from Morgan Stanley maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), with a price target of $172.00. The company’s shares closed last Wednesday at $111.00. According to TipRanks.com, Harrison is

Sarepta Therapeutics (SRPT) Gets a Buy Rating from Mizuho Securities

In a report released today, Difei Yang from Mizuho Securities maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), with a price target of $183.00. The company’s shares closed last Monday at $98.51. According to TipRanks.com, Yang has